PCSK-9 inhibitors: a new direction for the future treatment of ischemic stroke

Lin Zhou; Hongyu Zhang; Shuyi Wang; Hong Zhao; Yongnan Li; Juqian Han; Hongxu Zhang; Xiaoyuan Li; Zhengyi Qu

doi:10.3389/fphar.2023.1327185

PCSK-9 inhibitors: a new direction for the future treatment of ischemic stroke

Front Pharmacol. 2024 Jan 11:14:1327185. doi: 10.3389/fphar.2023.1327185. eCollection 2023.

Authors

Lin Zhou¹, Hongyu Zhang², Shuyi Wang³, Hong Zhao¹, Yongnan Li¹, Juqian Han¹, Hongxu Zhang¹, Xiaoyuan Li¹, Zhengyi Qu¹

Affiliations

¹ Department of Neurology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.
² Department of Neurosurgery, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.
³ State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Sun Yat-sen University, Guangzhou, China.

Abstract

Ischemic stroke, the most prevalent and serious manifestation of cerebrovascular disease, is the main cause of neurological problems that require hospitalization, resulting in disability and death worldwide. Currently, clinical practice focuses on the effective management of blood lipids as a crucial approach to preventing and treating ischemic stroke. In recent years, a great breakthrough in ischemic stroke treatment has been witnessed with the emergence and use of a novel lipid-lowering medication, Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor. And its remarkable potential for reducing the occurrence of ischemic stroke is being acknowledged. This article aims to provide a comprehensive review, encompassing the association between PCSK9 and the heightened risk of ischemic stroke, the mechanisms, and the extensive evidence supporting the proven efficacy of PCSK9 inhibitors in clinical practice. Through this present study, we can gain deeper insights into the utilization and impact of PCSK9 inhibitors in treating ischemic stroke.

Keywords: PCSK9 inhibitor; acute ischemic stroke; atherosclerosis; hyperlipidemia; platelets; stroke.

Publication types

Review

Grants and funding

The authors declare financial support was received for the research, authorship, and/or publication of this article. This work is supported by the Special funded research project of the Fourth Affiliated Hospital of Harbin Medical University (Number HTDSYTB202222).